Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.

Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM.

Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118-4. doi: 10.1016/j.eururo.2020.02.012. [Epub ahead of print]

PMID:
32143924
2.

A Phase 1 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-muscle Invasive BCG Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.

DeCastro GJ, Sui W, Pak JS, Lee SM, Holder D, Kates MM, Virk RK, Drake CG, Anderson CB, James B, Abate-Shen CT, McKiernan JM.

J Urol. 2020 Mar 2:101097JU0000000000000919. doi: 10.1097/JU.0000000000000919. [Epub ahead of print]

PMID:
32118506
3.

Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.

Haas CR, McKiernan JM.

Urol Clin North Am. 2020 Feb;47(1):47-54. doi: 10.1016/j.ucl.2019.09.007. Review.

PMID:
31757299
4.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
5.

The incidence, predictors, and survival of disappearing small renal masses on active surveillance.

Srivastava A, Patel HD, Gupta M, Joice GA, Schwen Z, Alam R, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

Urol Oncol. 2020 Feb;38(2):42.e1-42.e6. doi: 10.1016/j.urolonc.2019.10.005. Epub 2019 Nov 6.

PMID:
31704140
6.

Reply by Authors.

Sotimehin AE, Patel HD, Alam R, Gorin MA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

J Urol. 2020 Jan;203(1):207-208. doi: 10.1097/JU.0000000000000520. Epub 2019 Sep 3. No abstract available.

PMID:
31479394
7.

Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma.

González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G.

Eur J Surg Oncol. 2019 Oct;45(10):1983-1992. doi: 10.1016/j.ejso.2019.05.009. Epub 2019 May 15.

PMID:
31155470
8.

Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations.

Anderson CB, Lipsky M, Nandula SV, Freeman CE, Matthews T, Walsh CE, Li G, Szabolcs M, Mansukhani MM, McKiernan JM, Murty VV.

Genes Chromosomes Cancer. 2019 May 21. doi: 10.1002/gcc.22766. [Epub ahead of print]

PMID:
31112346
9.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
10.

Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study.

Sotimehin AE, Patel HD, Alam R, Gorin MA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

J Urol. 2019 May;201(5):886-892. doi: 10.1097/JU.0000000000000033. Erratum in: J Urol. 2019 Nov;202(5):1059.

PMID:
30694934
11.

The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria.

Gonzalez AN, Lipsky MJ, Li G, Rutman MP, Cooper KL, Weiner DM, Badalato G, Decastro GJ, Wenske S, McKiernan JM, Anderson CB.

Urology. 2019 Apr;126:34-38. doi: 10.1016/j.urology.2019.01.011. Epub 2019 Jan 22.

PMID:
30677457
12.

Use of delayed intervention for small renal masses initially managed with active surveillance.

Gupta M, Alam R, Patel HD, Semerjian A, Gorin MA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

Urol Oncol. 2019 Jan;37(1):18-25. doi: 10.1016/j.urolonc.2018.10.001. Epub 2018 Nov 13.

PMID:
30446459
13.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3.

PMID:
30190111
14.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. Review.

PMID:
30109483
15.

Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study.

Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

BJU Int. 2019 Jan;123(1):42-50. doi: 10.1111/bju.14490. Epub 2018 Aug 9.

16.

Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort.

Marra G, Gontero P, Brattoli M, Filippini C, Capitanio U, Montorsi F, Daneshmand S, Huang WC, Linares Espinós E, Martínez-Salamanca JI, McKiernan JM, Zigeuner R, Libertino JA.

Urol Oncol. 2018 Jul;36(7):339.e1-339.e8. doi: 10.1016/j.urolonc.2018.04.007. Epub 2018 May 24.

PMID:
29801993
17.

Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.

Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, Decastro GJ, McKiernan JM, Anderson CB.

J Urol. 2018 Nov;200(5):1005-1013. doi: 10.1016/j.juro.2018.05.078. Epub 2018 May 19.

PMID:
29787740
18.

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.

Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, Bergren SK, Pietzak EJ, Anderson CB, Benson MC, Coleman JA, Taylor BS, Abate-Shen C, McKiernan JM, Al-Ahmadie H, Solit DB, Shen MM.

Cell. 2018 Apr 5;173(2):515-528.e17. doi: 10.1016/j.cell.2018.03.017.

19.

Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Danzig MR, Mallin K, McKiernan JM, Stadler WM, Sridhar SS, Morgan TM, Bochner BH, Lee CT.

Cancer. 2018 Jun 15;124(12):2507-2514. doi: 10.1002/cncr.31372. Epub 2018 Apr 6.

20.

Analysis of evidence within the AUA's clinical practice guidelines.

Antoine SG, Small AC, McKiernan JM, Shah O.

Can J Urol. 2018 Feb;25(1):9168-9178. Review.

PMID:
29524971
21.

Surgical Complications of Urinary Diversion.

Anderson CB, McKiernan JM.

Urol Clin North Am. 2018 Feb;45(1):79-90. doi: 10.1016/j.ucl.2017.09.008. Review.

PMID:
29169453
22.

Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer.

Moran GW, Li G, Robins DJ, Matulay JT, McKiernan JM, Anderson CB.

Bladder Cancer. 2017 Oct 27;3(4):245-258. doi: 10.3233/BLC-170134.

23.

Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP.

Urol Oncol. 2018 Feb;36(2):79.e11-79.e17. doi: 10.1016/j.urolonc.2017.10.008. Epub 2017 Nov 10.

PMID:
29129353
24.

Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.

Whalen MJ, Pak JS, Lascano D, Ahlborn D, Matulay JT, McKiernan JM, Benson MC, Wenske S.

Clin Genitourin Cancer. 2018 Apr;16(2):e425-e435. doi: 10.1016/j.clgc.2017.10.007. Epub 2017 Oct 16.

PMID:
29113772
25.

Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.

Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, DeCastro G, Anderson C, Drake C, Benson M, McKiernan JM.

Urology. 2018 Jan;111:116-121. doi: 10.1016/j.urology.2017.09.003. Epub 2017 Oct 12.

PMID:
29032239
26.

Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry.

Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, Johnson MH, Gausepohl H, Riffon MF, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

J Urol. 2018 Mar;199(3):641-648. doi: 10.1016/j.juro.2017.09.087. Epub 2017 Sep 23.

PMID:
28951284
27.

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy.

Sui W, Lim EA, Joel Decastro G, McKiernan JM, Anderson CB.

Bladder Cancer. 2017 Jul 27;3(3):181-189. doi: 10.3233/BLC-170107.

28.

Active surveillance is superior to radical nephrectomy and equivalent to partial nephrectomy for preserving renal function in patients with small renal masses: Results from the DISSRM registry.

Danzig MR, Ghandour RA, Chang P, Wagner AA, Pierorazio PM, Allaf ME, McKiernan JM.

Urol Oncol. 2017 Mar;35(3):116. doi: 10.1016/j.urolonc.2016.05.011.

PMID:
28215846
29.

Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.

Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, McKiernan JM.

Urology. 2017 May;103:149-153. doi: 10.1016/j.urology.2017.01.018. Epub 2017 Feb 2.

PMID:
28163086
30.

Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival.

Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R.

J Surg Oncol. 2016 Nov;114(6):764-768. doi: 10.1002/jso.24395. Epub 2016 Aug 26.

31.

Prevalence of Research Publication Misrepresentation Among Urology Residency Applicants and Its Effect on Match Success.

Pak JS, Pagano MJ, Cooper KL, McKiernan JM, Badalato GM.

Urology. 2017 Jan;99:5-9. doi: 10.1016/j.urology.2016.08.055. Epub 2016 Oct 14.

PMID:
27751726
32.

A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention.

Patel HD, Riffon MF, Joice GA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Trock BJ, Allaf ME, Pierorazio PM.

J Urol. 2016 Nov;196(5):1356-1362. doi: 10.1016/j.juro.2016.04.073. Epub 2016 Apr 30.

PMID:
27140071
33.

Outcomes and Prognostic Factors of Primary Urethral Cancer.

Sui W, RoyChoudhury A, Wenske S, Decastro GJ, McKiernan JM, Anderson CB.

Urology. 2017 Feb;100:180-186. doi: 10.1016/j.urology.2016.09.042. Epub 2016 Oct 5.

PMID:
27720774
34.

A Prospective Randomized Trial of the Effects of Early Enteral Feeding After Radical Cystectomy.

Deibert CM, Silva MV, RoyChoudhury A, McKiernan JM, Scherr DS, Seres D, Benson MC.

Urology. 2016 Oct;96:69-73. doi: 10.1016/j.urology.2016.06.045. Epub 2016 Jul 8.

PMID:
27402372
35.

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM.

J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. Review.

PMID:
27317986
36.

Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer.

Motamedinia P, Scott AN, Bate KL, Sadeghi N, Salazar G, Shapiro E, Ahn J, Lipsky M, Lin J, Hruby GW, Badani KK, Petrylak DP, Benson MC, Donovan MJ, Comper WD, McKiernan JM, Russo LM.

PLoS One. 2016 May 4;11(5):e0154507. doi: 10.1371/journal.pone.0154507. eCollection 2016.

37.

The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.

Haas CR, Barlow LJ, Badalato GM, DeCastro GJ, Benson MC, McKiernan JM.

J Urol. 2016 Jun;195(6):1704-9. doi: 10.1016/j.juro.2016.01.087. Epub 2016 Jan 22.

PMID:
26807928
38.

Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry.

Danzig MR, Chang P, Wagner AA, Allaf ME, McKiernan JM, Pierorazio PM.

Curr Urol Rep. 2016 Jan;17(1):4. doi: 10.1007/s11934-015-0564-0. Review.

PMID:
26711846
39.

The Correlation of Media Ranking's "Best" Hospitals and Surgical Outcomes Following Radical Cystectomy for Urothelial Cancer.

Lascano D, Finkelstein JB, Barlow LJ, Kabat D, RoyChoudhury A, Caso JR, DeCastro GJ, Gold W, McKiernan JM.

Urology. 2015 Dec;86(6):1104-12. doi: 10.1016/j.urology.2015.07.049. Epub 2015 Sep 25.

PMID:
26408500
40.

Reoperative Retroperitoneal Surgery: Etiology and Clinical Outcome.

Woldu SL, McKiernan JM.

Urol Clin North Am. 2015 Aug;42(3):381-92. doi: 10.1016/j.ucl.2015.05.001. Review.

PMID:
26216825
41.

Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.

Lascano D, Pak JS, Kates M, Finkelstein JB, Silva M, Hagen E, RoyChoudhury A, Bivalacqua TJ, DeCastro GJ, Benson MC, McKiernan JM.

Urol Oncol. 2015 Oct;33(10):426.e1-12. doi: 10.1016/j.urolonc.2015.06.002. Epub 2015 Jul 9.

42.

Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation.

Pak JS, Lascano D, Kabat DH, Finkelstein JB, RoyChoudhury A, DeCastro GJ, Gold W, McKiernan JM.

Urol Oncol. 2015 Oct;33(10):426.e13-9. doi: 10.1016/j.urolonc.2015.06.001. Epub 2015 Jul 7.

PMID:
26162487
43.

Renal cell carcinoma: risks and benefits of nephron-sparing surgery for T1 tumors.

Ghandour RA, Danzig MR, McKiernan JM.

Adv Chronic Kidney Dis. 2015 Jul;22(4):258-65. doi: 10.1053/j.ackd.2015.03.006. Review.

PMID:
26088069
44.

Predicting Renal Parenchymal Loss after Nephron Sparing Surgery.

Meyer A, Woldu SL, Weinberg AC, Thoreson GR, Pierorazio P, Matulay JT, Benson MC, DeCastro GJ, McKiernan JM.

J Urol. 2015 Sep;194(3):658-63. doi: 10.1016/j.juro.2015.03.098. Epub 2015 Mar 25.

PMID:
25818030
45.

Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry.

Danzig MR, Ghandour RA, Chang P, Wagner AA, Pierorazio PM, Allaf ME, McKiernan JM.

J Urol. 2015 Oct;194(4):903-9. doi: 10.1016/j.juro.2015.03.093. Epub 2015 Mar 23.

PMID:
25813449
46.

Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes.

Berg WT, Danzig MR, Pak JS, Korets R, RoyChoudhury A, Hruby G, Benson MC, McKiernan JM, Badani KK.

Prostate. 2015 Jul 1;75(10):1085-91. doi: 10.1002/pros.22992. Epub 2015 Mar 21.

PMID:
25809289
47.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Aug;194(2):304-308. doi: 10.1016/j.juro.2015.02.2948. Epub 2015 Mar 19.

48.

National estimated costs of never events following radical prostatectomy.

Deibert CM, Kates M, McKiernan JM, Spencer BA.

Urol Oncol. 2015 Sep;33(9):385.e1-6. doi: 10.1016/j.urolonc.2014.08.002. Epub 2015 Mar 11.

PMID:
25770748
49.

Hypermetabolic residual retroperitoneal mass after chemotherapy for primary seminoma.

Pak JS, Shapiro E, Margolskee EM, McKiernan JM.

Urology. 2015 May;85(5):987-990. doi: 10.1016/j.urology.2015.01.016. Epub 2015 Mar 10. No abstract available.

PMID:
25769778
50.

Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.

Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME.

Eur Urol. 2015 Sep;68(3):408-15. doi: 10.1016/j.eururo.2015.02.001. Epub 2015 Feb 16.

PMID:
25698065

Supplemental Content

Loading ...
Support Center